Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Yamin, R.
    • Other Affiliation: Rockefeller University
  • Jones, A.T.
    • Other Affiliation: Rockefeller University
  • Hoffmann, H.-H.
    • Other Affiliation: Rockefeller University
  • Schäfer, A.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Kao, K.S.
    • Other Affiliation: Rockefeller University
  • Francis, R.L.
    • Other Affiliation: Rockefeller University
  • Sheahan, T.P.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Baric, R.S.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Rice, C.M.
    • Other Affiliation: Rockefeller University
  • Ravetch, J.V.
    • Other Affiliation: Rockefeller University
  • Bournazos, S.
    • Other Affiliation: Rockefeller University
Abstract
  • Monoclonal antibodies with neutralizing activity against SARS-CoV-2 have demonstrated clinical benefits in cases of mild-to-moderate SARS-CoV-2 infection, substantially reducing the risk for hospitalization and severe disease1–4. Treatment generally requires the administration of high doses of these monoclonal antibodies and has limited efficacy in preventing disease complications or mortality among hospitalized patients with COVID-195. Here we report the development and evaluation of anti-SARS-CoV-2 monoclonal antibodies with optimized Fc domains that show superior potency for prevention or treatment of COVID-19. Using several animal disease models of COVID-196,7, we demonstrate that selective engagement of activating Fcγ receptors results in improved efficacy in both preventing and treating disease-induced weight loss and mortality, significantly reducing the dose required to confer full protection against SARS-CoV-2 challenge and for treatment of pre-infected animals. Our results highlight the importance of Fcγ receptor pathways in driving antibody-mediated antiviral immunity and exclude the possibility of pathogenic or disease-enhancing effects of Fcγ receptor engagement of anti-SARS-CoV-2 antibodies upon infection. These findings have important implications for the development of Fc-engineered monoclonal antibodies with optimal Fc-effector function and improved clinical efficacy against COVID-19 disease.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Nature
Page start
  • 465
Page end
  • 470
Language
  • English
ISSN
  • 1476-4687

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details s41586-021-04017-w.pdf 2022-01-03 Public Download